Within the myocardium, IL-6-type cytokines convey their signals predominantly through the signal transducer and activator of transcription 3 pathway via a glycoprotein 130 (gp130) receptor subunit. 5 The circulating levels of the (J.J.V.M.). The online-only Data Supplement is available at http://circheartfailure.ahajournals.org/lookup/suppl/
I nflammation is involved in the pathogenesis of heart failure (HF). 1, 2 Although an inflammatory response is required for tissue repair after myocardial infarction, 3 prolonged or excessive inflammation may be maladaptive, leading to myocardial dysfunction and left ventricular (LV) remodeling. 4 Thus, although short-lived activation of interleukin-6 (IL-6) and related cytokines may be protective during ischemia, persistent activation of these mediators may lead to the development of cardiac hypertrophy and HF. 5, 6 In line with this, increased plasma IL-6 levels, proportional to disease severity, have been shown in patients with chronic HF of both ischemic and nonischemic causes, and high IL-6 concentrations have been associated with increased morbidity and mortality in these patients. 5, [7] [8] [9] Furthermore, 2 large genetic meta-analyses of >200 000 participants recently proposed a causative link between IL-6 signaling and coronary heart disease. 10, 11 January 2013 common receptor subunit, soluble gp 130 (sgp130), could potentially reflect the activity of the whole IL-6 family, including myocardial activation. We, and others, have reported elevated sgp130 levels in patients with HF, 7, 12 but information on the prognostic relevance of sgp130 in HF is still limited. 13 In addition, comparisons of sgp130 and IL-6, as 2 markers of activity in the IL-6 cytokine family, for risk prediction in large HF cohorts are still lacking.
Accordingly, we investigated the association of sgp130 and IL-6 with outcomes in a subset of patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial, a large multicenter trial evaluating the effects of rosuvastatin in elderly patients with chronic, systolic HF of ischemic origin.
Methods

Patients and Study Procedures
The design and principal findings of CORONA have been reported in detail. 14 Briefly, patients aged ≥60 years with chronic HF attributed to ischemic heart disease, defined as (1) medical history or ECG signs of myocardial infarction, or (2) other data suggesting an ischemic cause (eg, wall motion disturbances on echocardiography or history of other occlusive atherosclerotic disease [ie, earlier stroke, intermittent claudication, percutaneous coronary intervention]), who were in New York Heart Association classes II to IV, with an LV ejection fraction ≤40% (≤35% if New York Heart Association class II), were eligible for inclusion. The trial complied with the Declaration of Helsinki and was approved by the Ethics Committees of the participating hospitals. All patients provided written informed consent. Patients were randomly assigned to rosuvastatin 10 mg/day or matching placebo, once-daily. The present study was an optional, predefined substudy of the main CORONA trial that included patients from centers capable of collecting the necessary blood samples. Baseline characteristics of the study population according to quintile values of sgp130 are shown in Table 1 . Although in general similar to the main CORONA study, there were some modest but significant differences in the baseline characteristics between this substudy and the complete study population ( Table I in 
Study Outcomes and Definitions
The primary predefined outcome was the composite of death from cardiovascular (CV) causes, nonfatal myocardial infarction, and nonfatal stroke, analyzed as time to the first event. The secondary predefined outcomes were (1) all-cause mortality, (2) CV mortality (with an additional analysis of cause-specific death from a CV cause), (3) any coronary event (ie, sudden death, fatal or nonfatal myocardial infarction, performance of percutaneous coronary intervention or coronary artery bypass graft surgery, ventricular defibrillation by an implantable cardioverter-defibrillator, resuscitation from cardiac arrest, or hospitalization for unstable angina pectoris), and (4) the number of hospitalizations for CV causes, unstable angina, and worsening of HF (WHF). Details on the definition and adjudication of all outcomes are described elsewhere, as are data on C-reactive protein (CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). [14] [15] [16] [17] 
Blood Sampling and Biochemical Analyses
Soluble gp130, IL-6, and troponin T (TnT) were measured from blood samples taken after an overnight fast. All other blood samples were nonfasting and analyzed on fresh samples at a central laboratory (Medical Research Laboratories, Zaventem, Belgium). NT-proBNP was analyzed using a commercially available assay (Roche Diagnostics, Basel, Switzerland). An immunonephelometric high-sensitivity method was used to measure CRP (Dade Behring, Atterbury, UK; sensitivity 0.04 mg/L). Plasma IL-6 was measured with a Randox multiplex cytokine high-sensitivity assay (Randox Laboratories Ltd, Crumlin, Co, Antrim, UK) with a detection limit of 0.4 pg/mL and inter-and intra-assay coefficient of variation of <20%. Seventeen patients had undetectable IL-6 levels. Serum TnT was analyzed with a high-sensitivity assay on a Roche Modular E170 platform with a lower detection limit of 3 ng/L (Roche Diagnostics). Serum sgp130 was measured by enzyme immunoassay (R&D Systems, Minneapolis, MN). The detection limit of the assay was 40 pg/mL, with interassay coefficient of variation of 5.9% and intra-assay coefficient of variation for high (1:100 dilutions) and low levels (1:400 dilutions) of 7.8% and 9.4%, respectively. All patients had detectable sgp130 concentrations. Furthermore, sgp130 showed a median intraindividual (n=8) diurnal variation over 3 time points of 8.8% (P=0.37), with no difference between fasting and nonfasting sgp130 levels (P=0.57). When analyzing sgp130 in serum samples over 4-point dilutions from the upper limit of the assay, we found a mean coefficient of variation of 7% (SD 1.7), indicating no, or only minor, matrix effects.
Statistical Analysis
Soluble gp130 was initially evaluated as a log-transformed, continuous variable and found to predict fatal outcomes, with no associations with the primary end point or hospitalizations (Table II in the online-only Data Supplement). A restricted cubic spline analysis with 5 knots revealed nonlinearity of risk for all-cause mortality (significant end point for continuous sgp130 with the highest number of events), with a marked increase in poor outcome per unit increase in sgp130 for those patients with the highest sgp130 concentrations ( Figure 1A) . The turning point for the restricted cubic spline curve corresponded approximately to the transition between the fourth and the fifth quintile of sgp130. We subsequently dichotomized sgp130 by the fifth versus the fourth lower quintiles in all further analyses. Plasma IL-6 displayed linearity of risk in the restricted cubic spline analysis and was included as a log-transformed, continuous variable in multivariable analyses.
Differences between the top quintile and the bottom 4 quintiles of sgp130 were tested with Student t test for normally distributed baseline variables, Fisher exact test for categorical data, and Wilcoxon rank-sum test for non-normally distributed variables. Trends over sgp130 quintiles were tested with the Cuzick extension of the Wilcoxon rank-sum test, and all baseline variables with a P value for trend <0.05 were included in a multivariable analysis to identify degree of association with sgp130.
Survival analyses were conducted using the Cox proportional hazard regression model where sgp130 was included in a version of the 3-stage model described elsewhere, 17 which included mainly clinical variables at step 1 (LV ejection fraction, New York Heart Association class, age, body mass index, diabetes mellitus, sex, intermittent claudication, and heart rate). At step 2, the estimated glomerular filtration rate and apolipoprotein B/apolipoprotein A-1 ratio were included in the model. At stage 3, the log-transformed plasma concentrations of NT-proBNP, IL-6 and CRP were included, and, finally, at stage 4, the log-transformed serum concentration of TnT was included. Harrell C-statistic was calculated for all end points using the multivariable model with and without sgp130, and the difference between the C-statistics was estimated. We calculated C-statistics both without (step 3) and with TnT values (step 4) ( Table 2 ). To correct for overoptimism associated with validating a model in the same material from which it is developed, we implemented a jack-knife cross-validation approach, where predictions for each observation were obtained from models developed on the remaining observations. These cross-validated probabilities were used to calculate jack-knife C-statistics. Recently, calculation of net reclassification improvement (NRI) has been suggested for the evaluation of the prognostic usefulness of a biomarker. 18 In particular, when no established risk categories exist, the use of a category-free NRI has been advocated. 19 We, therefore, calculated the category-free NRI after adding sgp130 to the multivariable model at step 3 and step 4. Confidence intervals and P values for NRI were determined by boot-strapping with Clinical and biochemical baseline characteristics stratified by quintile values of sgp130. CRP, NT-proBNP, IL-6, TnT, and sgp130 are displayed as median value (25th-75th percentiles). Other variables are shown as number (percentage of total) or as mean (SD) where appropriate. ACE indicates angiotensin-converting enzyme; ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IL-6, interleukin 6; LDL, low-density lipoprotein; MDRD, modification of diet in renal disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; P, trend, probability value for trend across all quintiles; P, Q5, probability value for fifth quintile compared with all lower quintiles; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; sgp130, soluble glycoprotein 130; and TnT, troponin T.
Results
Serum sgp130 was measured at baseline and at 3 months in 1452 patients. Patients in the top quintile of sgp130 were more likely to be in atrial fibrillation, take digoxin, and had slightly higher heart rates (Table 1) . They also had lower cholesterol and higher NT-proBNP and TnT. In addition, patients in higher quintiles had more diabetes mellitus, slightly worse renal function, lower LV ejection fraction, and were more likely to be taking loop and thiazide diuretics in combination. In multivariable regression modeling, diabetes mellitus, digitalis use, use of loop and thiazide diuretics combined, and TnT remained associated with sgp130. TnT was the strongest determinant of sgp130, but explained only ≈2.5% of the variation in baseline sgp130 concentration.
IL-6 and sgp130 Levels and Association With Outcomes
During a median follow-up of 955 (25th-75th percentiles, 817-1103) days, 411 patients reached a primary end point and 425 patients died. Kaplan-Meier plots for all-cause and CV mortality revealed a markedly reduced survival for patients in sgp130 Q5 compared with all lower quintiles combined ( Figure 1B and 1C) .
When adjusting for demographic and clinical variables (step 1) in a 4-step multivariable analysis, sgp130 was associated with all-cause mortality, death because of CV causes, including death from WHF, and hospitalization because of WHF. However, sgp130 was associated with neither the primary nor the coronary end point ( Table 2 ). The inclusion of medications and extended medical history in an expanded Cox model did not alter these associations substantially (Table III in the online-only Data Supplement). The associations with mortality remained significant after adjusting for apolipoprotein B/ apolipoprotein A-1 ratio and estimated glomerular filtration rate (step 2). After correcting for NT-proBNP, IL-6 and CRP (step 3), and TnT (step 4) sgp130 remained a strong predictor for overall mortality and death from CV causes, including death from WHF, with little change in hazard ratio from the unadjusted model (Table 2) . Importantly, although related to sgp130, log-transformed, continuous IL-6 showed no association with any of the end points after adjustment for CRP and NT-proBNP (Table IV in 
the online-only Data Supplement).
Although area under curve analyses revealed limited discriminatory value of sgp130 alone ( Table 3) , addition of sgp130 in the multivariable analyses did not substantially alter effects of other variables (Table V in the online-only Data Supplement), suggesting incremental value of sgp130 and a noncompeting relationship to conventional risk factors and established biomarkers. This finding is further underscored by highly significant continuous NRIs for both all-cause (NRI 0.24; P<0.001) and CV mortality (NRI 0.22; P=0.006) when sgp130 was added to the multivariable models in step 3 (Figure 2 and Table  2 ). However, when accounting for TnT (step 4), sgp130 did not enhance risk prediction for any end points (Table 2) . Finally, sgp130 used as a continuous variable carried similar prognostic information in models adjusted for clinical variables alone, but when adjusted for NT-proBNP, the association with CV death was of only borderline significance (P=0.06), and significance for all outcomes was lost after adjusting for TnT (Table  II in 
Effect of Rosuvastatin Treatment on IL-6-and sgp130 Levels and Clinical Outcomes
Plasma IL-6 and serum sgp130 concentrations were similar at baseline and 3-month follow-up (continuous variable) both in patients assigned to placebo and rosuvastatin (P=0.99 and -4) , as a predictor of outcome. All hazard ratios (HR) are given as HR (95% confidence interval). ApoA-1 indicates apolipoprotein A-1; ApoB, apolipoprotein B; C index, Δ, difference in C index between adjusted models with and without inclusion of sgp130, corresponding (P value); CRP, C-reactive protein; CV, cardiovascular; LVEF, left ventricular ejection fraction; NRI, net reclassification improvement calculated from C indexes for adjusted models with and without inclusion of sgp130, corresponding (P value); NYHA, New York Heart Association; and WHF, worsening heart failure. *C index, Δ: difference in C index between adjusted models with and without inclusion of sgp130, corresponding P value. The models are adjusted as follows: †Step 1: LVEF, NYHA functional class, age, body mass index, diabetes mellitus, sex, intermittent claudication and heart rate. ‡Step 2: All variables from step 1, as well as ApoB/Apo A-1 ratio and estimated glomerular filtration rate. §Step 3: All variables from step 2, as well as NT-proBNP, IL-6, and CRP. ‖Step 4: All variables from step, 3 as well as troponin T. 0.36, respectively). No interaction was observed between neither IL-6 nor sgp130 and treatment group. Furthermore, sgp130 performed similarly in multivariable analyses in both the total (Table 2 ) and the placebo arm (Table VI in the onlineonly Data Supplement) of the study population.
Discussion
In this post hoc analysis of CORONA, we found that serum concentrations of sgp130, but not IL-6, were associated with fatal outcomes in a large population of elderly patients with chronic systolic HF of ischemic origin. We, and others, have demonstrated elevated levels of sgp130 in HF patients, with increasing levels according to disease severity. 7, 12, 20 However, few patients (n<100 in each study) were included in these reports. Gwechenberger et al 13 also reported an association between sgp130 and WHF, independently of NT-proBNP, in a small HF population of mixed cause. We now show, in a large population of HF patients with many events, that serum levels of sgp130 are associated with all-cause and CV mortality, including death from WHF, even after adjusting for NT-proBNP, CRP, IL-6, and TnT. To our knowledge, this is the first large-scale evaluation of the predictive power of sgp130 in HF.
The ability to reflect several upstream pathogenic pathways is a desirable feature of a biomarker. 21 The capacity of sgp130 to mirror the activity of several IL-6-related cytokines, of which many have been implicated in the pathogenesis of HF, 5,6 may account for its association with fatal outcomes in this analysis. In contrast to IL-6, sgp130 was associated with all fatal outcomes, except for sudden death, in the fully adjusted Cox model. This suggests that sgp130 might better reflect IL-6-type activity than IL-6 itself. From a practical point of view, IL-6 circulates at low levels (<10 pg/mL), often just above the detection limit of the assay, whereas sgp130 circulates at high concentrations (>100 ng/mL), making it more suitable as a clinical biomarker.
Soluble gp130 acts as a decoy receptor (R) for IL-6/sIL-6Rα complexes, when present in molar excess. 22 We hypothesize that sgp130 expression might be a compensatory response to limit IL-6 trans-signaling. In line with this, we suggest that considerably elevated sgp130 levels in patients with HF may reflect markedly enhanced gp130/signal transducer and activator of transcription 3 signaling in these patients. Although gp130-mediated signaling may confer cardioprotective properties through compensatory hypertrophy, tissue repair, and reduced apoptosis, 23 continuous and markedly increased activation of this signaling, potentially reflected by increased sgp130 levels, might have deleterious effects. 24 It is conceivable that the nonlinear risk increase seen for sgp130 in the present study may reflect a shift from compensatory to detrimental gp130-mediated signaling in relation to particularly high levels of sgp130.
In contrast to its association with fatal end points, sgp130 was not associated with the primary end point that included contributions from multiple disease mechanisms (ie, HF/ LV remodeling, atherosclerotic/vascular disease, intracranial hemorrhage). It is unlikely that the prognostic usefulness of sgp130 for all aforementioned disease mechanisms would be equally prominent. In fact, experimental studies suggest that inhibition of IL-6 trans-signaling could reduce rather than enhance atherogenesis. 25 The association between sgp130 levels and atherosclerosis may, therefore, be more complex, which again could influence its lack of association with the primary end point.
Recent evidence supports targeting of IL-6 signaling as a therapeutic strategy for reducing CV disease. 10, 11 The novel fusion protein sgp130Fc, which mimics natural, circulating sgp130, selectively inhibits IL-6 trans-signaling. 26 We hypothesize that measurements of sgp130 might be used to stratify patients most likely to benefit from sgp130Fc therapy, on the basis of ongoing, excessive IL-6 trans-signaling. The first human phase I study of sgp130Fc in chronic inflammatory diseases is scheduled for this year, 26 and it is tempting to suggest that similar studies should be performed in chronic HF.
Herein, we demonstrate that sgp130 is associated with all-cause and CV mortality and death from WHF also after multivariable adjustment. Applying sgp130 concentrations to adjusted multivariable models without TnT resulted in significant continuous NRIs for all-cause and CV mortality. However, sgp130 did not enhance risk prediction in our study population when TnT was accounted for. Area under curve analyses favored NT-proBNP as the best single marker for all end points and also demonstrated limited isolated discriminatory power of sgp130 (Table 3) . Still, new biomarkers might offer information on pathophysiological processes poorly reflected by today's state-of-the-art biomarkers, despite having lower receiver operating characteristics. Although NT-proBNP, and potentially also TnT, is a strong predictor of adverse outcome in patients with HF, it is unlikely that these biomarkers could reflect all pathogenic pathways that are involved in this complex disorder.
The present study examined multiple end points in a large HF population with a considerable number of events. However, for some subgroup analyses, including the interaction of sgp130 with rosuvastatin, there were relatively few events, and, therefore, these data should be interpreted cautiously. The discriminatory properties of sgp130 alone (Table 3) were limited in our population, implying that at present, the clinical usefulness of sgp130 is questionable. Also, not all markers (eg, TnT) were analyzed in all patients, which may have influenced the power of our analyses. In addition, we used a cut point derived from an analysis of one end point (all-cause mortality) on all other outcomes, which may have influenced the results. However, continuous sgp130 performed similarly to this cut point in the Cox regression, and the risk of substantially skewing the results in favor of all-cause mortality, therefore, seems limited. Our study was performed in trial patients aged ≥60 years, with LV systolic dysfunction and ischemic heart disease and a low prevalence of non-CV comorbidity (eg, chronic obstructive pulmonary disease). Thus, the results may not apply to all patients with HF. Also, we could not include an acknowledged HF risk model (eg, Seattle HF risk score) in the multivariable analyses as we did not have all the requisite variables. Finally, there is a need for more standardized methods for measuring sgp130, with an established normal range, before it is ready for use in clinical practice.
In conclusion, serum sgp130 was associated with fatal outcomes in patients with chronic systolic HF of ischemic cause, but did not seem to predict vascular events, and sgp130 did not enhance risk prediction when TnT was accounted for. Nonetheless, our findings may suggest a role for sustained activation of the gp130/signal transducer and activator of transcription 3 signaling pathway in the pathogenesis of HF, and the role of IL-6-related cytokines as a target for therapy in HF should be explored further. Furthermore, larger studies in more heterogeneous HF populations have to be performed before advocating implementation of sgp130 as a biomarker in clinical practice.
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CLINICAL PERSPECTIVE
Soluble glycoprotein 130 (sgp130) is a decoy receptor for the central proinflammatory cytokine interleukin-6 (IL-6), a marker associated with heart failure (HF) development and myocardial remodeling. IL-6 was also recently causally implicated as a mediator in the pathogenesis of coronary heart disease, and several experimental studies suggest targeting of IL-6 signaling as a therapeutic strategy for reducing cardiovascular disease. Soluble gp130 has been suggested to reflect the activity of IL-6-related cytokines. To determine the role of circulating sgp130 in the prediction of fatal and nonfatal outcomes in HF, we investigated serum levels of sgp130 in a large contemporary cohort of older patients with systolic HF, receiving modern pharmacological therapy, randomly assigned to statin therapy or placebo in a double-blind fashion. Sgp130 independently predicted fatal outcomes and improved risk prediction after adjustment for conventional risk markers, as well as C-reactive protein, IL-6, and N-terminal pro-B-type natriuretic peptide. However, when also accounting for troponin T, sgp130 remained independently predictive of mortality, but no longer provided incremental value in risk assessment as assessed by net reclassification improvement scores. In contrast, IL-6 was not associated with any end points after multivariable adjustment. Our data support involvement of IL-6 type signaling in chronic HF and suggest that serum sgp130 might partly reflect unmodified biological events in HF progression. Measurements of sgp130 might be used in risk stratification of patients with HF and possibly also to identify patients most likely to benefit from IL-6 inhibition.
